C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.

[1]  Y. Caliskan,et al.  Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? , 2017, American Journal of Nephrology.

[2]  Jai Radhakrishnan,et al.  A proposal for standardized grading of chronic changes in native kidney biopsy specimens. , 2017, Kidney international.

[3]  F. Petitprez,et al.  Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. , 2017, Blood.

[4]  G. Ardissino,et al.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[5]  Jai Radhakrishnan,et al.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. , 2016, Journal of the American Society of Nephrology : JASN.

[6]  G. Remuzzi,et al.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. , 2016, Molecular immunology.

[7]  T. Cavero,et al.  Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. , 2015, Kidney international.

[8]  R. Fukuzawa,et al.  Membranoproliferative glomerulonephritis and C3 glomerulonephritis: Frequency, clinical features, and outcome in children , 2015, Nephrology.

[9]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[10]  L. Morando,et al.  Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments , 2014, Kidney international.

[11]  P. O'kelly,et al.  C3 glomerulopathy: clinicopathologic features and predictors of outcome. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[12]  V. D’Agati,et al.  Toward a working definition of C3 glomerulopathy by immunofluorescence. , 2014, Kidney international.

[13]  V. D’Agati,et al.  C3 glomerulopathy: consensus report , 2013, Kidney international.

[14]  S. Nasr,et al.  C3 glomerulonephritis associated with monoclonal gammopathy: a case series. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  G. Appel,et al.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN , 2012, Nature Reviews Nephrology.

[16]  J. Grünfeld,et al.  Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. , 2012, Kidney international.

[17]  V. D’Agati,et al.  C3 glomerulopathy: what's in a name? , 2012, Kidney international.

[18]  S. Nasr,et al.  C3 Glomerulonephritis: Clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up , 2012, Kidney international.

[19]  L. Katz,et al.  Causes of alternative pathway dysregulation in dense deposit disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[20]  V. Frémeaux-Bacchi,et al.  C3 glomerulopathy: a new classification , 2010, Nature Reviews Nephrology.

[21]  Fernand,et al.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. , 2009, Kidney international.

[22]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[23]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.